

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 06/09/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/607,930	06/27/2003	Balwinder S. Bhatti	T103 1530.1	8695
26158 7:	590 06/09/2004	EXAMINER		INER
	ARLYLE SANDRIDG	DESAI, RITA J		
P.O. BOX 7037 ATLANTA, GA 30357-0037			ART UNIT	PAPER NUMBER
			1625	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/607,930	BHATTI ET AL.			
Office Action Summary	Examiner	Art Unit			
	Rita J. Desai	1625			
The MAILING DATE of this communication ap	pears on the cover sheet with the	correspondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep. If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	.136(a). In no event, however, may a reply be ti oly within the statutory minimum of thirty (30) da I will apply and will expire SIX (6) MONTHS fron te, cause the application to become ABANDON!	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on	·				
2a) This action is FINAL . 2b) ☑ Thi	·				
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1-44 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-44 are subject to restriction and/or	awn from consideration.				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the E	· · · · · · · · · · · · · · · · · · ·				
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document * See the attached detailed Office action for a list 	nts have been received. Its have been received in Applicat prity documents have been receiv au (PCT Rule 17.2(a)).	ion No ed in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date					
Notice of Draftsperson's Patent Drawing Review (PTO-946) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date		Patent Application (PTO-152)			

Art Unit: 1625

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claim 1-11, 21-31 and 41-44 in part, drawn to compounds and pharmaceuticals wherein the core is a diazospiro nonane., wherein the Cy group is a pyridyl, classified in class 546, 514 and in various subclasses.
- II. Claims 1-11, 21-31 and 41-44 in part, drawn to compounds and pharmaceuticals wherein the core is a diazospiro decane and the cy group is pyridyl, classified in class 546, subclass 18.
- III. Claims 1-11, 21-31, and 41-44 in part, drawn to compounds and pharmaceutical compositions wherein the core is a diazospiro octane and the cy group is a pyridyl, classified in class 546 and various subclasses.
- IV. Claims 1-11, 21-31, 41-44 in part, drawn to compounds and pharmaceutical compositions wherein the core is a diazaspiro undecane and the cy is a pyridyl, classified in class 546, subclass 18.
- V. Claims 1-11, 21-31, 41-44 in part, drawn to compounds and pharmaceutical compositions wherein the core is a, *spiro[1-azabicyclo[2.2.1]heptane-2,3'-pyrrolidine] classified in class 549, and various subclasses.
- VI. Claims 1-11, 21-31, 41-44 in part, drawn to compounds and pharmaceutical compositions, wherein the core is a spiro[1-azabicyclo[2.2.2]octane-2,3'-pyrrolidine], classified in class 549 and various subclasses.

Art Unit: 1625

VII. Claims 1-11, 21-31, 41-44 in part, drawn to compounds and pharmaceutical compositions, wherein the core is a other than the ones given in the above groups, classified in various classes and subclasses. A further election of a single disclosed species is required. May be subject to further restriction.


VIII. Claims 12-20, 32-40, drawn to various method of treating, classified in class 514 and various subclasses. May be subject to restriction, since there are various method of treating.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have a different core and hence different bonding and properties.

When a preliminary search was done on the core, it did not run.

See below:-



=> s 11

STRUCTURE TOO LARGE - SEARCH ENDED

A structure in your query is too large. You may delete attributes or atoms to reduce the size of the structure and try again.

Art Unit: 1625

Inventions I-VII and VIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case there are numerous drugs that are used to treat the the different diseases as claimed, hence the process for using the product as claimed can be practiced with another materially different product.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicants preserve their right to file a divisional on the cancelled non-elected subject matter, without prejudice in due course.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II to VIII or vice versa, restriction for examination purposes as indicated is proper.

REJOINDER:- If applicants elect a group from groups I-VII and if it were to be found allowable then ONE method of treating claim limited to the same scope as the compounds and pharmaceutical compositions, shall be rejoined and allowed provided it is free from all 112 issues.

Art Unit: 1625

A telephone call was made to Mr. Massey on 6/3/04 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rita J. Desai whose telephone number is 571-272-0684. The examiner can normally be reached on Monday - Friday,9:30 am to 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1625

Rita J. Desai Primary Examiner Art Unit 1625

R.D. June 3, 2004 6 | 3/04